Cambridge Allergy Ltd: Camallergy Awarded £1.1 M Funding Under Innovate UK Biomedical Catalyst Award for Novel Peanut Allergy Treatment
-Company to provide corporate update at upcoming Global Life Sciences investor conference
Cambridge Allergy Ltd ( Camallergy or the Company ), a biopharmaceutical company dedicated to providing innovative, patient-centric treatments for life-threatening food allergies, today announced it has been awarded
£1.1M funding under the Innovate UK Biomedical Catalyst Award program administered by Innovate UK, the United Kingdom s research and innovation agency.
The
£1.1M in non-dilutive funding will be used to accelerate the Company s peanut allergy immunotherapy, CA002, for planned Phase 3 clinical trials. The project commences in the first quarter of 2021, and as part of the project s success, the Company intends to file its investigation new drug application with the FDA and submit a clinical trials application to the MHRA and EMA.